Additional file 4: Fig. S2. TDP-43 pathology, granular fuzzy astrocytes (GFAs), argyrophilic grains, hippocampal sclerosis, and tissue degeneration in the amygdala in representative cases. A–F Pathological findings in a case with Braak NFT stage II, Thal phase 0, amygdala GFA stage 2, Saito AG stage III, and LATE-NC stage 2. A, B Phosphorylated TDP-43 accumulation in the amygdala A and dentate gyrus in the hippocampus B. pS409/410 immunohistochemistry. Scale bar: 25 μm. C A GFA in the amygdala. AT8 immunohistochemistry. Scale bar: 25 μm. D AGs in the amygdala. Gallyas method. Scale bar: 25 μm. E Hippocampal sclerosis. Hematoxylin-eosin stain. Scale bar: 100 μm. F Severe loss of neurons with gliosis in the amygdala. Hematoxylin-eosin stain. Scale bar: 25 μm. G–L Pathological findings in a case with Braak stage II, Thal phase 0, amygdala GFA stage 4, Saito AG stage III, and LATE-NC stage 0. G This case lacked phosphorylated TDP-43-positive lesion in any region. The amygdala. pS409/410 immunohistochemistry. Scale bar: 25 μm. H, I GFAs in the amygdala. AT8 immunohistochemistry. Scale bar: 25 μm. J AGs in the amygdala. Gallyas method. Scale bar: 25 μm. K Neither loss of pyramidal neurons nor gliosis is noted in the hippocampal CA1. Hematoxylin-eosin stain. Scale bar: 100 μm. L Severe neuronal loss with gliosis in the amygdala. Hematoxylin-eosin stain. Scale bar: 25 μm.